Microscopic Polyangiitis Market By Diagnosis Type (Blood Tests, Urinalysis, Biopsy, Imaging Techniques), By Treatment Type (Corticosteroids, Immunosuppressants, Biologics, Plasma Exchange), By Distribution Channel (Hospitals, Clinics, Specialty Pharmacies, Online Pharmacies), By End-User (Hospitals, Clinics, Research Institutes), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Microscopic Polyangiitis Market was valued at USD 1.4 billion in 2024-e and will surpass USD 3.3 billion by 2030; growing at a CAGR of 13.2% during 2025 - 2030.

The Microscopic Polyangiitis (MPA) market is driven by advancements in diagnostic techniques, which have significantly improved early diagnosis and treatment outcomes. Blood tests are the most widely used diagnostic method, as they help identify specific biomarkers such as anti-neutrophil cytoplasmic antibodies (ANCA), which are critical for diagnosing ANCA-associated vasculitis (AAV), including MPA. Blood tests are preferred due to their non-invasive nature, availability, and ability to provide quick results, making them essential for early-stage diagnosis and monitoring disease progression.

Diagnosis Type Segment Is Largest Owing to Blood Tests

The Microscopic Polyangiitis (MPA) market is driven by advancements in diagnostic techniques, which have significantly improved early diagnosis and treatment outcomes. Blood tests are the most widely used diagnostic method, as they help identify specific biomarkers such as anti-neutrophil cytoplasmic antibodies (ANCA), which are critical for diagnosing ANCA-associated vasculitis (AAV), including MPA. Blood tests are preferred due to their non-invasive nature, availability, and ability to provide quick results, making them essential for early-stage diagnosis and monitoring disease progression.

Blood tests are the largest subsegment in the diagnosis segment due to their high accuracy in detecting inflammatory markers associated with MPA. The ease of use and the ability to conduct blood tests in various healthcare settings, such as hospitals, clinics, and research institutes, contribute to their popularity. As diagnostic technologies improve, blood tests will continue to play a pivotal role in identifying MPA, driving growth in this subsegment.

Treatment Type Segment Is Largest Owing to Corticosteroids

Corticosteroids remain the largest segment in the treatment of Microscopic Polyangiitis due to their effectiveness in reducing inflammation and controlling disease flare-ups. These drugs have been the cornerstone of MPA management for years, offering rapid relief from symptoms by suppressing immune responses. Corticosteroids are commonly used in combination with other immunosuppressive therapies to control the disease, making them a critical treatment option for many patients.

Corticosteroids are effective in treating the acute phases of MPA and preventing further organ damage, particularly in patients with kidney involvement, which is common in MPA cases. The widespread availability and relatively low cost of corticosteroids compared to biologics and other treatments ensure their dominant position in the market. Despite their long-term side effects, such as bone loss and weight gain, their efficacy and affordability contribute to their continued dominance in the treatment segment.

Distribution Channel Segment Is Largest Owing to Hospitals

Hospitals are the largest distribution channel for MPA treatment products, as they serve as the primary healthcare setting for diagnosing and treating severe cases of the disease. Hospitals offer specialized care, including advanced diagnostic tools and treatment options such as corticosteroids, immunosuppressants, and biologics. Given the complexity and severity of MPA, patients typically seek treatment at hospitals, where they can access multidisciplinary care from nephrologists, rheumatologists, and other specialists.

Hospitals are also equipped with the infrastructure to manage critical cases of MPA that require immediate intervention, such as plasma exchange therapy or immunosuppressive therapy. With their ability to provide both inpatient and outpatient services, hospitals remain the leading distribution channel for MPA treatments, a trend that is expected to continue as healthcare systems evolve to support patients with complex diseases.

End-User Segment Is Largest Owing to Hospitals

Hospitals are the largest end-user segment in the MPA market, driven by the need for specialized care in managing this rare and severe autoimmune disease. Hospitals are equipped with the necessary infrastructure and medical expertise to treat MPA patients, especially those with kidney failure or other complications. Given the high complexity of MPA and the intensive treatment regimens it often requires, hospitals remain the primary setting for diagnosis, treatment, and patient management.

Hospitals not only serve as the primary point of care for patients but also play a significant role in the research and development of new therapies for MPA. The ongoing advancements in treatment options, such as biologic drugs and targeted therapies, are often initiated and tested in hospital settings, further reinforcing their dominance as the largest end-user segment.

Region Segment Is Largest Owing to North America

North America is the largest region in the MPA market, driven by advanced healthcare infrastructure, high awareness levels, and significant investments in research and development. The United States, in particular, has a well-established healthcare system capable of diagnosing and treating rare diseases like MPA effectively. North America also benefits from the presence of leading pharmaceutical companies and research institutions that focus on innovative treatments for autoimmune diseases, including MPA.

The region is supported by a high number of healthcare professionals skilled in the treatment of rare diseases, contributing to the widespread use of advanced diagnostic tools and cutting-edge therapies. As the prevalence of autoimmune diseases continues to rise in North America, the demand for MPA treatments is expected to grow, further solidifying the region’s dominant position in the global market.

Recent Developments:

• GlaxoSmithKline launched Benlysta (belimumab) as an approved treatment for autoimmune diseases, including microscopic polyangiitis, further expanding its portfolio in rare diseases.
• AbbVie submitted a new biologic drug candidate for the treatment of ANCA-associated vasculitis, with promising results in the microscopic polyangiitis patient population.
• Merck acquired Aimmune Therapeutics to diversify its immunology portfolio, with future plans to explore treatments for autoimmune diseases like microscopic polyangiitis.
• Bristol-Myers Squibb’s new biologic, targeting autoimmune vasculitis, received FDA approval for use in patients with microscopic polyangiitis and other related conditions.

List of Leading Companies:

• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Pfizer Inc.
• Amgen Inc.
• AstraZeneca plc
• Johnson & Johnson
• AbbVie Inc.
• Novartis AG
• Sanofi
• Biogen Inc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• UCB S.A.

Report Scope: